Trends and spatial distribution of pneumonia admissions and deaths among children <5 years, Uganda, 2013–2021

Mercy Wendy Wanyana, Richard Migisha, Patrick King, Lilian Bulage, Benon Kwesiga, Daniel Kadobera, Alex Riolexus Ario, Julie R. Harris
doi: https://doi.org/10.1101/2024.02.13.24302770

Abstract

Background Pneumonia is the second leading cause of hospital admissions and deaths among children <5 years old in Uganda. In 2013, Uganda adopted various interventions to protect, prevent, and improve the treatment of pneumonia under the Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea (GAPPD), including the introduction of the pneumococcal conjugate vaccine (PCV) into routine immunization schedule. However, little is known about the impact of these interventions on pneumonia admissions and deaths. We described the trends and spatial distribution of pneumonia hospital admissions and mortality among children <5 years in Uganda, 2013–2021.

Methods We analysed secondary data on pneumonia admissions and deaths from the District Health Information System version 2 during 2013–2021. Reporting rates were calculated as the percentage of expected complete monthly health facility reports submitted to the national surveillance database. The proportion of pneumonia cases admitted and case-fatality rates (CFRs) for children <5 years were calculated for children <5 years presenting at the outpatient department. At national, regional, and district levels, pneumonia mortality rates were calculated per 100,000 children <5 years. The Mann-Kendall Test was used to assess trend significance.

Results There were 753,978 pneumonia admissions and 13,632 (2%) deaths during 2013–2021. Reporting rates ranged from 78–92%. The overall proportion of pneumonia cases admitted among children <5 years was 23%. The overall CFR was 0.41%, and the overall pneumonia mortality rate among children <5 years was 21 deaths per 100,000. From 2013 to 2021, there were declines in the proportion of pneumonia cases admitted (33% to 15%; p=0.051), mortality rates (26/100,000 to 13 per 100,000; p=0.01), and CFR (0.61% to 0.24%; p=0.01), concomitant with increasing PCV coverage. Kotido District had a persistently high proportion of pneumonia cases that were admitted (>30%) every year while Kasese District had persistently high mortality rates (68-150 deaths per 100,000 children <5 years).

Conclusion Pneumonia admissions, mortality, and case fatality among children <5 years declined during 2013–2021 in Uganda after the introduction of PCV. However, with these trends it is unlikely that Uganda will meet the 2025 GAPPD targets. There is therefore a need to review implementation of existing interventions, identify gaps in order to highlight priority actions to further accelerate declines.

Background

In 2019, pneumonia was the leading infectious cause of death globally among children <5 years old, accounting for 14% of all deaths in this age group1. Half of the pneumonia cases and deaths among children <5 years are reported in sub-Saharan Africa2. Worldwide, pneumonia in childhood is commonly caused by Streptococcus pneumoniae3. The pneumococcal conjugate vaccine (PCV) contains serotypes that are commonly associated with invasive and mucosal pneumonia among children <5 years and can reduce both incidence and severity of disease4. While pneumonia incidence among children <5 years declined globally during 2000 to 2015, the same time period saw an increase in pneumonia requiring admissions in sub-Saharan Africa2,5.

In Uganda, pneumonia is the second leading cause of all hospital admissions among children <5 years6, most of which is caused by Streptococcus pneumoniae7. To reduce this burden, Uganda and other low-income countries committed in 2013 to implementing the World Health Organization’s integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD)8. This initiative included the introduction of the 10-valent PCV (PCV10) into the routine immunisation schedule. PCV10 targets the commonest pneumococcal serotypes documented in Uganda before its introduction (6B,19F, and 23F) as well as serotypes 1, 4, 5, 7F,9V,14, and 18C9,10. Three doses of PCV10 (PCV1, 2, and 3) are given to children at 6, 10, and 12 weeks of age11. Other low-cost interventions put in place with GAPPD include exclusive breastfeeding for the first six months and continued breastfeeding with appropriate complementary feeding thereafter; use of simple, standardized guidelines for the identification and treatment of pneumonia in the community through integrated community case management of childhood illnesses; and reduction of household air pollution with improved stoves8. With these interventions, implemented in 2013, Uganda is attempting to reduce the incidence of pneumonia requiring admission by 75% in children <5 years from 2013 to 2025 and reduce mortality from pneumonia in children <5 years of age to <3 per 1,000 live births by 2025.

Currently, little is documented on Uganda’s progress towards these goals. Previous studies conducted in Uganda assessed the prevalence of pneumonia at specific timepoints and may not reflect Uganda’s progress over time12,13. Additionally, these studies were conducted in sub-regions and may not be generalisable to the entire country or show meaningful spatial differences. We assessed the temporal trends and spatial distribution of pneumonia admissions and mortality among children <5 years in Uganda from 2013–2021 to assess progress towards these goals.

Methods

Study setting

We utilized pneumonia data generated from all health facilities in Uganda. The Uganda health system classifies health facilities into various levels based on their capacities. In Uganda, outpatient pneumonia cases are managed at all levels, while those with pneumonia requiring admission are managed at health centres III and IV, general and regional referral hospitals, and national referral hospitals, all of which have in-patient services14. Patients are also referred as needed from lower-level facilities (health centres) to higher-level facilities (hospitals).

Data source

We conducted a descriptive study using routinely-collected pneumonia surveillance data from the District Health Information System version 2 (DHIS2) during 2013–2021. DHIS2 is an electronic database that was officially adopted in 201215. It contains data on priority diseases, conditions, and events of public health importance, including pneumonia from 2013 to-date16. Aggregate data on pneumonia cases, admissions, and deaths from both outpatient and inpatient monthly reports (Health Management Information System forms [HMIS] 105 and HMIS 108) from 2013–2021 were used for this study.

Study variables, data management, and analysis

We obtained aggregate data on pneumonia cases and admissions among children <5 years to calculate the annual proportion of pneumonia cases admitted. A pneumonia admission was defined as a hospital stay in a person with pneumonia as a primary diagnosis, based on the International Classification of Disease-10 framework. A pneumonia case at the outpatient department was defined as pneumonia as a primary diagnosis based on the International Classification of Disease-10 framework in a patient not requiring a hospital stay. We calculated the proportion of pneumonia cases admitted using pneumonia admissions <5 years as a numerator and total pneumonia cases <5 years presenting at the outpatient department as a denominator. (All admitted patients with pneumonia pass through the outpatient department before admission.) Pneumonia deaths were defined as in-patient deaths with pneumonia recorded as the primary cause of death. We calculated pneumonia mortality using pneumonia deaths among children <5 years as a numerator and estimated annual population data for children <5 years from the Uganda Bureau of Statistics (UBOS) as a denominator. Case-fatality rates (CFRs) were calculated as the proportion of pneumonia cases <5 years at health facilities who died at the facility. Reporting rates for cases and deaths were calculated as the percentage of the expected monthly reports that were submitted to DHIS2 from 2013 to 2021. PCV 3 vaccine coverage was calculated as the percentage of the target population who received 3 doses of the PCV10 in a given year based on data obtained from DHIS2. Although the PCV10 vaccine was introduced in 2013, official rollout to the entire country started in 201417. PCV 3 vaccine coverage was therefore calculated from 2014 to 2021.

We downloaded data in Excel and imported it into EpiInfo 7 software (CDC, Atlanta, USA) for analysis. Annual proportion of pneumonia cases admitted, mortality rates, and case-fatality rates were calculated at national and regional levels. Line graphs were used to describe national and regional trends. The Mann-Kendall test was conducted to assess significance of the trends. Choropleth maps drawn using QGIS software were used to show the spatial distribution of pneumonia admissions and mortality in the country.

Ethical Considerations

Our study utilized routinely generated aggregated surveillance data with no personal identifiers in health facility in-patient monthly reports through the DHIS2. The Ministry of Health (MoH) of Uganda through the office of the Director General Health Services gave approval to access data from the DHIS2. We stored the abstracted data set in a password-protected computer and only shared it with the investigation team. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.§

§See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

Results

National trends in the proportion of pneumonia cases admitted among children <5 years with pneumonia in Uganda, 2013-2021

During the study period, reporting rates for both admissions and deaths increased from 78% to 92% (Kendall’s score=24, p=0.017). There was a total of 3,560,974 outpatient pneumonia cases and 753,978 admitted pneumonia cases reported among children <5 years. The overall proportion of pneumonia cases <5 years admitted was 21% (range: 15-34%). Overall, there was a 50% decline in the proportion of pneumonia cases admitted over the study period, from 30% to 15% (Kendall’s score=-20, p=0.051), concurrent with increasing PCV 3 vaccine coverage from 60% to 91% (Figure 1).

Figure 1:
Figure 1:

National trend in proportion of pneumonia cases admitted among children <5 years with pneumonia, Uganda, 2013-2021; PCV: Pneumococcal conjugate vaccine. Data for 2013 were not available.

National trends in pneumonia mortality among children <5 years, Uganda, 2013–2021

During the study period, there were 13,632 pneumonia-related deaths among children <5 years. The overall pneumonia mortality rate was 21 deaths per 100,000 children <5 years (Figure 2). There was a 50% decline in pneumonia mortality rates from 26 to 13 per 100,000 children <5 years (Kendall’s score = −14, p=0.005).

Figure 2:
Figure 2:

National trend in pneumonia mortality among children <5 years, Uganda, 2013-2021; PCV: Pneumococcal conjugate vaccine. Data for 2013 were not available.

Pneumonia case-fatality rate among children <5 years, Uganda, 2013–2021

The overall CFR was 0.41% children <5 years with pneumonia (Range: 0.25–0.69). There was a 61% decline from 0.61% to 0.24% over the evaluation period (Kendall’s score = −26, p=0.009) (Figure 3).

Figure 3:
Figure 3:

Trends in pneumonia case-fatality rate among children <5 years, Uganda, 2013-2021

Regional trends of pneumonia cases admitted, mortality rate and case fatality rate among children <5 years, Uganda, 2013-2021

Both the proportion of pneumonia cases admitted and pneumonia mortality rates among children <5 years were higher in the Northern Region than in the Western, Eastern, and Central Regions (Table 1). Case-fatality rates were higher in the Central, Northern, and Western regions than in the Eastern Region. Declines in mortality rates were observed over the study period across all regions, while case-fatality rates declined in the Northern and Western regions (Table 1).

View this table:
Table 1:

Regional trends of pneumonia cases admitted, mortality rate, and case fatality rate among children <5 years Uganda, 2013-2021. Kendall’s score and p­ value represents the presence or absence of a 9-year linear trend.

Spatial distribution of proportion of pneumonia cases admitted and mortality among children <5 years, Uganda, 2013-2021

Proportion of pneumonia cases among children <5 years that were admitted was generally highest in north-eastern Uganda. Kotido District had consistently high admissions rates of >40% throughout the study period (Figure 4).

Figure 4:
Figure 4:

Spatial distribution of proportion of pneumonia cases admitted among children <5 years, 2013-2021, Uganda

Kasese District (Figure 5) had consistently high pneumonia mortality throughout the review period ranging from 68 to 150 deaths per 100,000 children <5 years.

Figure 5:
Figure 5:

Spatial distribution of pneumonia mortality rate among children <5 years, 2013-2021, Uganda

Discussion

We described the trends and spatial distribution of pneumonia hospital admissions, mortality, and case-fatality among children <5 years in Uganda from 2013–2021. Over the 9 years, there was a decline in both the proportion of pneumonia cases that were admitted and deaths concomitant with an increase in PCV3 coverage.

After the introduction of PCV10 in Uganda in 2013, we found a ≥50% reduction in pneumonia cases admitted, mortality, and case-fatality rates among children <5 years over the next 9 years. These findings are in agreement with those in other African countries after PCV was introduced: a study in Burkina Faso identified a 34% reduction in pneumonia admissions among children <5 years five years after the introduction of PCV18, while another in Zambia found a 38% and 29% decline in pneumonia admissions among children aged <1 year and 1–4 years, respectively, three years after introduction of PCV19. Studies in South Africa and Rwanda have had similar findings20,21. The greater reductions in our study, compared to the others, could be related to the longer period of observation after the introduction of PCV in our study. Declines in admissions and case fatality rates observed in 2015 could also be attributable to the impact of the WHO-recommended admission criteria introduced in 201422. Before 2014, any child <5 years old with pneumonia (i.e., with fast breathing and/or chest indrawing) was recommended to be admitted. With the revisions in 2014, recommendations for admission were changed to pneumonia plus any danger signs, which would have led to declines in admissions. The revised treatment guidelines promoted outpatient treatment of pneumonia without danger signs with oral amoxicillin. This was a more effective and accessible treatment, and has been linked to a reduction in pneumonia deaths among children22.

We noted that the largest decline in case-fatality rates occurred from 2015 to 2016. It is unknown why this occurred, but it may be related to the 32% decline in new HIV infections between 2014 and 2015, which represented the largest decline in many years26. HIV is a key risk factor for pneumonia deaths among children <5 years linked and is associated with a 4-fold increased risk of pneumonia death27. Additional declines in pneumonia case-fatality rates even after 2015 might also reflect improvements in the quality of healthcare during the study period. Integrated community case management introduced at the start of the review period facilitated prompt diagnosis and access to antibiotics at the community level, improving appropriate care-seeking23. During the review period, there were also increases in access to electricity (both hydroelectricity and solar), especially at low-level health facilities over time, there is increased access to oxygen therapy thereby improving patient survival thus reducing case-fatality rates24,25.

The 50% decline in pneumonia admissions over the 9-year period was borderline significant, suggesting a smaller effect of the PCV on pneumonia admissions than on mortality or case-fatality28. While PCV reduces the severity and incidence of pneumonia among the strains it targets29, previous studies have shown that the introduction of PCV can lead to an increase in the proportion of pneumococcal pneumonia due to non-vaccine pneumococcal serotypes30,31. It is possible that in Uganda, like other African countries, other serotypes are taking the place of those targeted by PCV. A study in the Gambia indicated a 47% increase in pneumococcal pneumonia due to non-vaccine serotypes 3 years following PCV13 introduction32. Similarly, a 27% increase in pneumococcal pneumonia was observed in Botswana following introduction of PCV33. However, there are few data available on the current distribution of circulating serotypes in Uganda. The decline suggests that Uganda may be on track to reach the GAPPD target of a 75% reduction in admissions by 2025. Nonetheless, monitoring of trends in the circulating pneumococcal serotypes in the post-PCV era and maintaining other interventions to reduce the burden and impact of childhood pneumonia is important to ensuring that the reductions continue34.

Regional variations in the proportion of pneumonia cases admitted, pneumonia mortality, and case-fatality rates were observed. The highest proportion of pneumonia cases admitted and mortality were observed in the northern and eastern regions. These regions are characterised with higher levels of poverty and poor housing compared to other areas of the country, which are known to be associated with increased likelihood of pneumonia requiring admission and mortality35,36. There is a need to understand the factors associated with high burden of severe pneumonia in these regions to develop targeted interventions.

Our findings should be interpreted with the following limitations. We used inpatient data, which could lead to underestimation of the true pneumonia mortality by missing cases and deaths that occurred in communities. Secondly, we used aggregated secondary data, which lacked key variables to further explore trends across subcategories within this age group. Thirdly, we were unable to make before-and-after PCV10 comparisons of pneumonia admissions and deaths due to the lack of data before PCV10 introduction. As a result, we cannot assess the impact of the introduction of PCV10 on the observed trends of pneumonia admissions and deaths to the interventions introduced in 2013. Finally, despite reductions in pneumonia admissions and deaths with increasing PCV10 coverage, we cannot definitively attribute these reductions to PCV10. During this time period, other interventions, including exclusive breastfeeding for the first six months and continued breastfeeding with appropriate complementary feeding thereafter, increased access to antibiotics through integrated community case management of childhood illnesses, reduction of household air pollution with improved stoves, and increased access to oxygen therapy were implemented, and these also likely led to reductions.

Conclusion

Our findings demonstrate declines in pneumonia admissions, mortality rates, and case-fatality rates among children <5 years over the 9-year period following the introduction of PCV in Uganda. However, with these trends it is unlikely that Uganda will meet the 2025 targets. Reviewing the implementation of existing interventions and identification of gaps to highlight priority actions could further accelerate decline.

Data Availability

The datasets upon which our findings are based belong to the Uganda Public Health Fellowship Program and can be availed upon reasonable request from the corresponding author with permission from the Uganda Public Health Fellowship Program.

Acknowledgements

We would like to thank the Ministry of Health for providing access to DHIS2 data that was used for this analysis. We appreciate the technical support provided by the Division of Surveillance, Information and Knowledge Management, MoH. Finally, we thank the US-CDC for supporting the activities of the Uganda Public Health Fellowship Program.

List of abbreviations

DHIS2
District Health Information System version 2
GAPPD
Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea
HC
Health Centre
HMIS
Health Management Information System
PCV
Pneumococcal Conjugate Vaccine
UBOS
Uganda Bureau of Statistics

References

  1. 1.↵
    Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet Child Adolesc Heal. 2022 Feb;6(2):106–15.
    OpenUrl
  2. 2.↵
    Troeger CE, Khalil IA, Blacker BF, Biehl MH, Albertson SB, Zimsen SRM, et al. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis [Internet]. 2020 Jan 1;20(1):60–79. Available from: doi:10.1016/S1473-3099(19)30410-4
    OpenUrlCrossRef
  3. 3.↵
    O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet (London, England). 2009 Sep;374(9693):893–902.
    OpenUrl
  4. 4.↵
    Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2000 Jan;30(1):100–21.
    OpenUrl
  5. 5.↵
    McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. Lancet Glob Heal. 2019 Jan;7(1):e47–57.
    OpenUrlCrossRef
  6. 6.↵
    MoH M of HU. Ministry of Health Annual Sector Performance Report 2020/2021 [Internet]. Kampala, Uganda; 2021. Available from: http://library.health.go.ug/publications/performance-management/annual-health-sector-performance-report-financial-year-202021
  7. 7.↵
    Nantanda R, Hildenwall H, Peterson S, Kaddu-Mulindwa D, Kalyesubula I, Tumwine JK. Bacterial aetiology and outcome in children with severe pneumonia in Uganda. Ann Trop Paediatr. 2008 Dec;28(4):253–60.
    OpenUrlCrossRefPubMed
  8. 8.↵
    WHO (World Health Organisation). Ending preventable child deaths from pneumonia and diarrhoea by 2025: the integrated global action plan for pneumonia and diarrhoea (GAPPD). 2013;
  9. 9.↵
    Lindstrand A, Kalyango J, Alfvén T, Darenberg J, Kadobera D, Bwanga F, et al. Pneumococcal Carriage in Children under Five Years in Uganda-Will Present Pneumococcal Conjugate Vaccines Be Appropriate? PLoS One. 2016;11(11):e0166018.
    OpenUrl
  10. 10.↵
    Nackers F, Cohuet S, le Polain de Waroux O, Langendorf C, Nyehangane D, Ndazima D, et al. Carriage prevalence and serotype distribution of Streptococcus pneumoniae prior to 10-valent pneumococcal vaccine introduction: A population-based cross-sectional study in South Western Uganda, 2014. Vaccine [Internet]. 2017;35(39):5271–7. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X17310071
    OpenUrl
  11. 11.↵
    MoH (Minstry of Health Uganda). Routine Immunisation Question and Answer Booklet [Internet]. Kampala, Uganda; 2013. Available from: https://www.unicef.org/uganda/media/2776/file/Routine Immunisation Q & A booklet.pdf
  12. 12.↵
    Kiconco G, Turyasiima M, Ndamira A, Yamile OA, Egesa WI, Ndiwimana M, et al. Prevalence and associated factors of pneumonia among under-fives with acute respiratory symptoms: a cross sectional study at a Teaching Hospital in Bushenyi District, Western Uganda. Afr Health Sci. 2021 Dec;21(4):1701–10.
    OpenUrl
  13. 13.↵
    Ma C, Gunaratnam LC, Ericson A, Conroy AL, Namasopo S, Opoka RO, et al. Handheld Point-of-Care Lactate Measurement at Admission Predicts Mortality in Ugandan Children Hospitalized with Pneumonia: A Prospective Cohort Study. Am J Trop Med Hyg. 2019 Jan;100(1):37–42.
    OpenUrlPubMed
  14. 14.↵
    IHE (Institute for Health Metrics and Evaluation). Assessing Facility Capacity, Costs of Care, and Patient Perspectives [Internet]. Seattle; Available from: https://www.healthdata.org/sites/default/files/files/policy_report/2014/ABCE/Uganda/ABCE_Uganda_full_report_2014.pdf
  15. 15.↵
    Kiberu VM, Matovu JKB, Makumbi F, Kyozira C, Mukooyo E, Wanyenze RK. Strengthening district-based health reporting through the district health management information software system: the Ugandan experience. BMC Med Inform Decis Mak [Internet]. 2014;14(1):40. Available from: doi:10.1186/1472-6947-14-40
    OpenUrlCrossRefPubMed
  16. 16.↵
    MoH (Minstry of Health Uganda). National Technical Guidelines for Integrated Disease Surveillance and Response Third Edition [Internet]. 2021. Available from: https://www.afro.who.int/sites/default/files/2021-09/2_Uganda 3rd IDSR Tech Guideline_PrintVersion_10Sep2021.pdf
  17. 17.↵
    WHO (World Health Organisation). Uganda rolls out the Pneumococcal Conjugate Vaccine (PCV) [Internet]. 2014 [cited 2023 Dec 2]. Available from: https://www.afro.who.int/news/uganda-rolls-out-pneumococcal-conjugate-vaccine-pcv
  18. 18.↵
    Kaboré L, Ouattara S, Sawadogo F, Gervaix A, Galetto-Lacour A, Karama R, et al. Impact of 13-valent pneumococcal conjugate vaccine on the incidence of hospitalizations for all-cause pneumonia among children aged less than 5 years in Burkina Faso: An interrupted time-series analysis. Int J Infect Dis [Internet]. 2020 Jul 1;96:31–8. Available from: doi:10.1016/j.ijid.2020.03.051
    OpenUrlCrossRef
  19. 19.↵
    Mpabalwani EM, Lukwesa-Musyani C, Imamba A, Nakazwe R, Matapo B, Muzongwe CM, et al. Declines in Pneumonia and Meningitis Hospitalizations in Children Under 5 Years of Age After Introduction of 10-Valent Pneumococcal Conjugate Vaccine in Zambia, 2010–2016. Clin Infect Dis [Internet]. 2019 Sep 5;69(Supplement_2):S58–65. Available from: doi:10.1093/cid/ciz456
    OpenUrlCrossRef
  20. 20.↵
    Kleynhans J, Tempia S, Shioda K, von Gottberg A, Weinberger DM, Cohen C. Estimated impact of the pneumococcal conjugate vaccine on pneumonia mortality in South Africa, 1999 through 2016: An ecological modelling study. PLOS Med [Internet]. 2021 Feb 16;18(2):e1003537. Available from: doi:10.1371/journal.pmed.1003537
    OpenUrlCrossRef
  21. 21.↵
    Rurangwa J, Rujeni N. Decline in Child Hospitalization and Mortality After the Introduction of the 7-Valent Pneumococcal Conjugative Vaccine in Rwanda. Am J Trop Med Hyg. 2016 Sep;95(3):680–2.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    WHO (World Health Organisation). Revised who classification and treatment of childhood pneumonia at health facilities, 2014. Geneva WHO. 2021;
  23. 23.↵
    Kalyango JN, Alfven T, Peterson S, Mugenyi K, Karamagi C, Rutebemberwa E. Integrated community case management of malaria and pneumonia increases prompt and appropriate treatment for pneumonia symptoms in children under five years in Eastern Uganda. Malar J [Internet]. 2013;12(1):340. Available from: doi:10.1186/1475-2875-12-340
    OpenUrlCrossRefPubMed
  24. 24.↵
    Khogali A, Ahmed A, Ibrahim M, Karrar K, Elsheikh M, Abdelraheem E, et al. Building power-ful health systems: the impacts of electrification on health outcomes in LMICs. Psychol Health Med [Internet]. 2022 Dec 15;27(sup1):124–37. Available from: doi:10.1080/13548506.2022.2109049
    OpenUrlCrossRef
  25. 25.↵
    Turnbull H, Conroy A, Opoka RO, Namasopo S, Kain KC, Hawkes M. Solar-powered oxygen delivery: proof of concept. Int J Tuberc lung Dis Off J Int Union against Tuberc Lung Dis. 2016 May;20(5):696–703.
    OpenUrl
  26. 26.↵
    Uganda AIDS Commission. The Uganda HIV and AIDS country progress report July 2015-June 2016.
  27. 27.↵
    Wilkes C, Bava M, Graham HR, Duke T. What are the risk factors for death among children with pneumonia in low- and middle-income countries? A systematic review. J Glob Health. 2023 Feb;13:5003.
    OpenUrl
  28. 28.↵
    Hackshaw A, Kirkwood A. Interpreting and reporting clinical trials with results of borderline significance. BMJ [Internet]. 2011 Jul 4;343:d3340. Available from: http://www.bmj.com/content/343/bmj.d3340.abstract
    OpenUrl
  29. 29.↵
    Reyburn R, Tsatsaronis A, von Mollendorf C, Mulholland K, Russell FM. Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old. J Glob Health. 2023 Feb;13:5002.
    OpenUrl
  30. 30.↵
    Masomian M, Ahmad Z, Gew LT, Poh CL. Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines. 2020 Mar;8(1).
  31. 31.↵
    Ali MA, Okojokwu OJ, Adiekwuo RC, Robinson JW. Prevalence and serotypes of Streptococcus pneumoniae among under five children attending Toro general hospital, Bauchi State, Nigeria. Microbes Infect Dis [Internet]. 2023;4(2):468–76. Available from: https://mid.journals.ekb.eg/article_240662.html
    OpenUrl
  32. 32.↵
    Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infect Dis. 2016 Jun;16(6):703–11.
    OpenUrlPubMed
  33. 33.↵
    Patel SM, Shaik-Dasthagirisaheb YB, Congdon M, Young RR, Patel MZ, Mazhani T, et al. Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine. PLoS One. 2022;17(1):e0262225.
    OpenUrl
  34. 34.↵
    Du Q, Shi W, Yu D, Yao K. Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines. Hum Vaccin Immunother [Internet]. 2021 Dec 2;17(12):5628–37. Available from: doi:10.1080/21645515.2021.1985353
    OpenUrlCrossRef
  35. 35.↵
    Atamanov A, Malasquez Carbonel EA, Masaki T, Myers CA, Granguillhome Ochoa R, Sinha N. Uganda Poverty Assessment: Strengthening Resilience to Accelerate Poverty Reduction. 2022;
  36. 36.↵
    Azab SFAH, Sherief LM, Saleh SH, Elsaeed WF, Elshafie MA, Abdelsalam SM. Impact of the socioeconomic status on the severity and outcome of community-acquired pneumonia among Egyptian children: a cohort study. Infect Dis Poverty [Internet]. 2014;3(1):14. Available from: doi:10.1186/2049-9957-3-14
    OpenUrlCrossRefPubMed
Back to top
Posted February 14, 2024.
Download PDF
Data/Code
Email
Trends and spatial distribution of pneumonia admissions and deaths among children <5 years, Uganda, 2013–2021
Mercy Wendy Wanyana, Richard Migisha, Patrick King, Lilian Bulage, Benon Kwesiga, Daniel Kadobera, Alex Riolexus Ario, Julie R. Harris
medRxiv 2024.02.13.24302770; doi: https://doi.org/10.1101/2024.02.13.24302770
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area